eScholarship
metadata only
PTH treatment is effective in the Aga2/+ mouse model of moderate to severe osteogenesis imperfecta
Osteogenesis imperfecta (OI) is a genetically heterogenous disorder characterized by brittle bone and recurrent fractures. The majority of OI is clinically categorized into mild, moderate, severe, and perinatal lethal forms. A clinical study on the use of intermittent parathyroid hormone (PTH) as an
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Can Parathyroid Hormone Injections Reverse Glucocorticoid-induced Osteoporosis#969472
- The Role of Bone Marrow Microenvironment in Osteogenesis Imperfecta: Evidence from Single-Cell RNA Sequencing#1043972
- Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women#1086303
- The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta#854715
- Telescoping Nail in Osteogenesis Imperfecta#834326
Record · ID 922240
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive